trial
as of 2026-07-01D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
NCTId NCT00237848
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
72 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2005-02
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Yale UniversityLead Sponsor
Stanley Medical Research InstituteCollaborator
Donaghue FoundationCollaborator
US Department of Veterans AffairsCollaborator
VA Office of Research and DevelopmentCollaborator
Investigators
1
Deepak Cyril D'Souza, MDPrincipal Investigator
Sites
1 total
Bangalore, India
Facts & assertions
3 sourced
Enrollment
72
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
company
indication
investigator
person